Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?

about

Clinical effectiveness and safety of gemifloxacin versus cefpodoxime in acute exacerbation of chronic bronchitis: A randomized, controlled trial.In Vivo Pharmacokinetic and Pharmacodynamic Profiles of Antofloxacin against Klebsiella pneumoniae in a Neutropenic Murine Lung Infection Model.

P2860

Q34706478-008F253D-8A05-406E-AC39-90B38F3EFD0C Q38926294-45F59972-DF5C-433A-8876-362072DC9B33

P2860

Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?

Item

http://www.wikidata.org/entity/Q36728602

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Treating acute exacerbations o ...... respiratory fluoroquinolones?

@ast

Treating acute exacerbations o ...... respiratory fluoroquinolones?

@en

type

Item

label

Treating acute exacerbations o ...... respiratory fluoroquinolones?

@ast

Treating acute exacerbations o ...... respiratory fluoroquinolones?

@en

prefLabel

Treating acute exacerbations o ...... respiratory fluoroquinolones?

@ast

Treating acute exacerbations o ...... respiratory fluoroquinolones?

@en

P1476

Treating acute exacerbations o ...... respiratory fluoroquinolones?

@en

P2093

K Weiss

http://www.w3.org/2001/XMLSchema#string

M Balter

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis

A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin

Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis.

Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.

Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000.

Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatmen

Longitudinal assessment of antipneumococcal susceptibility in the United States.

Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

Improving care for patients with respiratory tract infections.

P304

1236-1242

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17279183

http://www.w3.org/2001/XMLSchema#string

P932

1783596

http://www.w3.org/2001/XMLSchema#string

Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?

about

P2860

P2860

Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P407

P433

P478

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P407

P433

P478

P577

P698

P932